M&A / Deals LEO Pharma to acquire gene therapy company Replay Pharmaceutical Business ReviewThe acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector.Gene Therapy PlatformRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant openingNext: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
